William McKenzie, MD
Pulmonary Disease · Panama City, FLNPI 1326060682
Payments from drug & device makers
Across 844 payments — averaging $427.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$174K
- Mylan Specialty L.p.$95K
- Sunovion Pharmaceuticals Inc.$21K
- Takeda Pharmaceuticals U.S.A., Inc.$21K
- Boehringer Ingelheim$18K
- Shire North American Group Inc$13K
- plus $20K from 25 others
What the payments were for
- Consulting fees$18,3505%
- Speaking & faculty fees$307,56985%
- Travel & lodging$19,9556%
- Food & beverage$14,8284%
- Education$1250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 289 | $173,978 |
| Mylan Specialty L.p. | 205 | $95,226 |
| Sunovion Pharmaceuticals Inc. | 27 | $20,608 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $20,517 |
| Boehringer Ingelheim | 65 | $17,743 |
| Shire North American Group Inc | 23 | $12,584 |
| Grifols USA, LLC | 19 | $8,731 |
| Viatris Specialty LLC | 20 | $4,957 |
| Verona Pharma, Inc. | 12 | $2,781 |
| Grifols Shared Services North America, Inc. | 1 | $660 |
| GSK | 35 | $599 |
| Sanofi | 9 | $354 |
| Regeneron Healthcare Solutions, Inc. | 12 | $307 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $244 |
| Electromed, Inc. | 16 | $225 |
| Harmony Biosciences LLC | 8 | $192 |
| Vifor Pharma, Inc. | 7 | $177 |
| Astellas Pharma US Inc | 7 | $139 |
| Amgen | 6 | $131 |
| Jazz Pharmaceuticals Inc. | 6 | $120 |
| 3b Medical, Inc. | 3 | $100 |
| Insmed, Inc. | 4 | $94 |
| Sumitomo Pharma America, Inc. | 5 | $84 |
| Merck | 3 | $57 |
| Philips North America LLC | 3 | $56 |
| Inspire Medical Systems, Inc. | 2 | $55 |
| Fisher & Paykel Healthcare Inc | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| United Therapeutics Corporation | 1 | $20 |
| Inogen, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$97,501
- BREZTRI$78,374
- FASENRA$37,264
- GLASSIA$32,169
- AIRSUPRA$28,412
- LONHALA MAGNAIR$20,162
- TEZSPIRE$11,077
- Prolastin-C Liquid$9,175
- DALIRESP$4,431
- BREZTRI AEROSPHERE$3,550
- Ohtuvayre$2,615
- SYMBICORT$2,116
- BEVESPI AEROSPHERE$1,350
- LUMRYZ$200
How this compares
$360,827 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 23 | $217,215 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $72,383 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $59,701 |
| Spiriva RespimatTiotropium Bromide | 38 | $38,031 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $36,391 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 46 | $23,391 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $22,152 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $14,465 |
| Ventolin HfaAlbuterol Sulfate | 137 | $13,118 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $12,985 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 245 | $10,968 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,882 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $3,356 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $2,996 |
| Roflumilast | 16 | $2,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $8,731 | $217,21523 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $173,978 | $108,760145 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $599 | $92,735106 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $17,743 | $74,42277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Panama City
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.